rinary angiotensinogen (AGT) becomes a biomarker for the selection of optimal antihypertensive drugs
- Conditions
- Hypertension
- Registration Number
- JPRN-UMIN000010931
- Lead Sponsor
- Kagawa University, Faculty of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 150
Not provided
1. Hypertensive emergency 2. Secondary hypertension 3. Under treatment of aldosterone antagonists in the 8 weeks before registration 4. Under treatment of steroid drugs or immunosuppressive drugs, or under a 2-week (or longer) treatment of non-steroidal ant-inflammatory drugs (NSAIDs). 5. Fasting glucose > 126 mg/dl or under treatment of oral hypoglycemic drugs. 6. Severe hepatic disease (GOT >= 150 IU or GPT >= 150 IU) 7. History of cardiovascular events (myocardial infarction, etc.) in the 6 months before registration 8. History of cerebrovascular events (cerebral infarction, etc.) in the 6 months before registration. 9. Patients with malignant tumorin the 6 months before registration 10. Pregnant (possibility also), or wanting to be pregnant 11. Other inadequacies
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.